0 Vectura Group PLC Analyst Ratings, Earnings, Dividends and Insider Trades | $VEC | LON:VEC | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Vectura Group PLC Company Profile (LON:VEC) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileToday's Chart Consensus Ratings for Vectura Group PLC (LON:VEC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Sell Rating(s), 8 Buy Rating(s)Consensus Rating:Buy (Score: 2.60)Consensus Price Target: GBX 148.88 Analysts' Ratings History for Vectura Group PLC (LON:VEC) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/5/2014JPMorgan Chase & Co.Reiterated RatingOverweightView 2/13/2014N+1 SingerReiterated RatingSellGBX 110View 2/13/2014FinnCapReiterated RatingBuyGBX 180View 2/5/2014JPMorgan Chase & Co.Reiterated RatingOverweightView 1/29/2014FinnCapReiterated RatingBuyGBX 180View 1/21/2014JPMorgan Chase & Co.Reiterated RatingOverweightView 1/14/2014N+1 SingerBoost Price TargetSellGBX 97 -> GBX 110View 1/14/2014FinnCapReiterated RatingBuyGBX 180View 1/6/2014JPMorgan Chase & Co.Boost Price TargetOverweightGBX 155 -> GBX 200View 12/19/2013InvestecBoost Price TargetBuyGBX 148 -> GBX 170View 12/19/2013Canaccord GenuityBoost Price TargetBuyGBX 125 -> GBX 150View 12/19/2013FinnCapReiterated RatingBuyGBX 140 -> GBX 180View 12/10/2013N+1 SingerReiterated RatingSellGBX 97View 12/5/2013Berenberg BankReiterated RatingBuyGBX 200View 11/19/2013N+1 SingerReiterated RatingSellGBX 97View 11/19/2013InvestecReiterated RatingBuyGBX 148View 11/19/2013Numis Securities LtdReiterated RatingBuyGBX 142View 11/19/2013FinnCapReiterated RatingBuyGBX 140View 11/13/2013Canaccord GenuityReiterated RatingBuyGBX 125View 10/22/2013FinnCapReiterated RatingBuyGBX 140View 10/15/2013Citigroup Inc.Reiterated RatingBuyGBX 142View 10/2/2013Citigroup Inc.Reiterated RatingBuy -> BuyGBX 142View 10/1/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightView 9/24/2013N+1 SingerDowngradeHold -> SellGBX 93 -> GBX 97View 9/24/2013Nplus1 BrewinDowngradeSellGBX 93 -> GBX 97View 9/23/2013Canaccord GenuityBoost Price TargetBuy -> BuyGBX 113 -> GBX 125View 9/23/2013N+1 SingerReiterated RatingHold -> HoldGBX 93View 9/20/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightView 9/5/2013InvestecReiterated RatingBuy -> BuyGBX 111 -> GBX 148View 8/28/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightView 8/13/2013Canaccord GenuityReiterated RatingBuy -> BuyGBX 113View 8/13/2013Shore Capital StockbrokersReiterated RatingBuy -> BuyView 8/6/2013N+1 SingerDowngradeBuy -> HoldGBX 93View 8/5/2013Citigroup Inc.Reiterated RatingBuy -> BuyGBX 142View 7/29/2013FinnCapBoost Price TargetBuy -> BuyGBX 110 -> GBX 140View 7/29/2013N+1 SingerBoost Price TargetBuy -> BuyGBX 91 -> GBX 93View 7/29/2013InvestecBoost Price TargetBuy -> BuyGBX 107 -> GBX 111View 7/4/2013N+1 SingerInitiated CoverageBuyGBX 91View 7/4/2013Nplus1 BrewinInitiated CoverageBuyGBX 91View 7/3/2013Citigroup Inc.Reiterated RatingBuy -> BuyGBX 142 -> GBX 142View 7/3/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightView 6/21/2013FinnCapReiterated RatingBuy -> BuyGBX 110 -> GBX 110View 6/20/2013InvestecInitiated CoverageBuyGBX 107View 6/10/2013Canaccord GenuityLower Price TargetBuy -> BuyGBX 120 -> GBX 113View 6/3/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightGBX 148 -> GBX 148View 5/22/2013JPMorgan Chase & Co.Boost Price TargetOverweight -> OverweightGBX 133 -> GBX 148View 5/21/2013Shore Capital StockbrokersReiterated RatingBuy -> BuyView 5/21/2013Canaccord GenuityReiterated RatingBuy -> BuyGBX 120 -> GBX 120View 5/21/2013Numis Securities LtdReiterated RatingBuy -> BuyGBX 118 -> GBX 118View 5/17/2013Berenberg BankReiterated RatingBuy -> BuyGBX 145 -> GBX 180View 5/13/2013Citigroup Inc.Reiterated RatingBuy -> BuyGBX 142 -> GBX 142View 5/13/2013FinnCapReiterated RatingBuy -> BuyGBX 110 -> GBX 110View 5/13/2013Canaccord GenuityReiterated RatingBuy -> BuyGBX 120 -> GBX 120View 5/7/2013Numis Securities LtdInitiated CoverageBuyGBX 118View 4/23/2013Canaccord GenuityReiterated RatingBuy -> BuyGBX 120 -> GBX 120View 4/3/2013Citigroup Inc.Reiterated RatingBuyGBX 140.62View (Data available from 3/9/2012 forward) Earnings History for Vectura Group PLC (LON:VEC)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for Vectura Group PLC (LON:VEC)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Vectura Group PLC (LON:VEC)No insider trades for this company have been tracked by Analyst Ratings Network About Vectura Group PLC Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura's products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company's pharmaceutical business consists of the research, development and commercialization of pharmaceutical products. Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development. The Company's products include NVA237, QVA149, VR315 EU & RoW, VR315 US, VR632 EU, VR632 US & RoW and VR315. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: LON Symbol: VEC CUSIP: Key Metrics: Previous Close: $0.0050 Day Moving Average: $N/A200 Day Moving Average: $N/A P/E Ratio: N/AP/E Growth: N/AMarket Cap: $N/ACurrent Quarter EPS Consensus Estimate: $N/A EPS Additional Links: View VEC on Google FinanceView VEC on Yahoo FinanceView VEC's Company Profile on ReutersSearch for Vectura Group PLC on Google Vectura Group PLC (LON:VEC) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.